Impact of eribulin on overall survival in patients with metastatic breast cancer with visceral disease.
L. T. Vahdat
Consultant or Advisory Role - Bristol-Myers Squibb (I); Eisai; GlaxoSmithKline
Honoraria - Bristol-Myers Squibb; Eisai (I); GlaxoSmithKline
Research Funding - Bristol-Myers Squibb; Eisai; GlaxoSmithKline
J. Cortes
Consultant or Advisory Role - Bristol-Myers Squibb; Eisai; GlaxoSmithKline
Honoraria - Bristol-Myers Squibb; Eisai; GlaxoSmithKline
Research Funding - Bristol-Myers Squibb; Eisai; GlaxoSmithKline
C. Twelves
Consultant or Advisory Role - Bristol-Myers Squibb; Eisai; GlaxoSmithKline
Honoraria - Bristol-Myers Squibb; Eisai; GlaxoSmithKline
Research Funding - Bristol-Myers Squibb; Eisai; GlaxoSmithKline
J. Wanders
Employment or Leadership Position - Eisai
S. Seegobin
Employment or Leadership Position - Eisai
C. Dutcus
Employment or Leadership Position - Eisai
J. O'Shaughnessy
Consultant or Advisory Role - Bristol-Myers Squibb; Eisai; GlaxoSmithKline
Honoraria - Bristol-Myers Squibb; Eisai; GlaxoSmithKline
Research Funding - Bristol-Myers Squibb; Eisai; GlaxoSmithKline